Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers.

Expert opinion on investigational drugs - 1 Dec 2022

Cioffi Raffaella, Galli Federica, Rabaiotti Emanuela, Candiani Massimo, Pella Francesca, Candotti Giorgio, Bocciolone Luca, De Marzi Patrizia, Mangili Giorgia, Bergamini Alice

Abstract excerpt

INTRODUCTION: Fallopian tube carcinoma (FC) as a single entity is a rare disease. Although its diagnosis is increasing thanks to the widespread use of prophylactic salpingectomy, there are no clinical trials exclusively designed for FC. AREAS COVERED: This review aims at identifying the most promising trials and future therapeutic pathways in the setting of FC. EXPERT OPINION: Hot topics in FC treatment include...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Platinum

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 36537209
DOI: 10.1080/13543784.2022.2160313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers.PMID 36537209Read ↗

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on the Chemotherapy in Clinical PracticeSemantic proximity Read ↗

Major clinical research advances in gynecologic cancer in 2017.Semantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanismsSemantic proximity Read ↗

[Understanding biology to identify new therapeutic targets beyond chemotherapy in ovarian granulosa cell tumors].Semantic proximity Read ↗

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insightsSemantic proximity Read ↗

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.Semantic proximity Read ↗

Zebrafish avatars: towards functional precision medicine in low-grade serous ovarian cancerSemantic proximity Read ↗

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read ↗

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS 2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectorsSemantic proximity Read ↗

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.